No abstract

No abstract

After we developed a saturated iron core type 35 kV/90 MVA superconductive fault current limiter and installed the device in a transmission network at Puji substation of China Southern Power Grid for live-grid operation in 2007, we continued our efforts in advancing this technology. A 220 kV/300 MVA device has been designed, manufactured and factory tested. This device differs from the 35 kV device in its form of electrical insulation even though the two devices have the same working principle and similar core structure. Improvements in the dc magnetization circuit and the cryogenic system were also achieved. This 220 kV/300 MVA superconductive fault current limiter has been installed and has passed all field tests at Shigezhuang substation in Tianjin, China. Trial operation is underway. This paper introduces the major design parameters, key functional specifications and some testing results of the device.

Imbalance of gut microbiota homeostasis is related to the occurrence of ulcerative colitis (UC), and probiotics are thought to modulate immune microenvironment and repair barrier function. Here, in order to reveal the interaction between UC and gut microbiota, we screened a new probiotic strain by 16S rRNA sequencing from Dextran Sulfate Sodium (DSS)-induced colitis mice, and explored the mechanism and clinical relevance. Lactobacillus johnsonii ( L. johnsonii ), as a potential anti-inflammatory bacterium was decreased colonization in colitis mice. Gavage L. johnsonii could alleviate colitis by specifically increasing the proportion of intestinal macrophages and the secretion of Il-10 with macrophages depleted model and in Il10 −/− mice. We identified this subset of immune cells activated by L. johnsonii as CD206 + macrophages IL−10 . Mechanistically, L. johnsonii supplementation enhanced the mobilization of CD206 + macrophages IL−10 through the activation of STAT3 in vivo and in vitro . In addition, we revealed that TLR1/2 was essential for the activation of STAT3 and the recognition of L. johnsonii by macrophages. Clinically, there was positive correlation between the abundance of L. johnsonii and the expression level of MRC1, IL10 and TLR1/2 in UC tissues. L. johnsonii could activate native macrophages into CD206 + macrophages and release IL-10 through TLR1/2-STAT3 pathway to relieve experimental colitis. L. johnsonii may serve as an immunomodulator and anti-inflammatory therapeutic target for UC.